Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23571410 | 0.98 | ODC1 (0.35) | MGMTODC1 | |
| SCHEMBL23226055 | 0.94 | MGMT (0.36) | MGMT | |
| SCHEMBL13658545 | 0.91 | ODC1 (0.33) | MGMTODC1 | |
| SCHEMBL25755568 | 0.89 | ODC1 (0.35) | ODC1 | |
| SCHEMBL25756204 | 0.87 | ODC1 (0.33) | ODC1 | |
| SCHEMBL14330842 | 0.86 | MGMT (0.41) | MGMT | |
| SCHEMBL16329221 | 0.86 | MGMT (0.41) | MGMT | |
| SCHEMBL13449873 | 0.86 | MGMT (0.41) | MGMT | |
| SCHEMBL13612332 | 0.86 | MGMT (0.41) | MGMT | |
| SCHEMBL13497925 | 0.86 | MGMT (0.41) | MGMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-10894091-B2 | Linker units and molecular constructs comprising the same | Immunwork Inc. (TW) | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | MGMT 4434/4885ODC1 4097/4885 |
| US-10894091-B2 | Linker units and molecular constructs comprising the same | CD2BP2, BCR, UACA | MGMT 2288/4885ODC1 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.